drugset / Trial / NCT00174239

Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.

NCT00174239

Phase 4 Terminated 220 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.

Timeline

Start
2004-07
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabergoline Small molecule
Subject Carbidopa Unknown
Subject Levodopa Small molecule

Indications